Author

B. H. Nelson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell-cell communication· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. J. Lum· 2 shared P. T. Hamilton· 2 shared A. De Reynies· 1 shared A. Gamboa· 1 shared A. Jiang· 1 shared A. Karsan· 1 shared A. Merchant· 1 shared A. Mezheyeuski· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. J. Lum

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance

S. Levesque, G. Carleton, V. Duque, C. Goupil, J.-P. Fiset, S. Villeneuve, E. Normandeau, G. Morin, N. Dumont, B. H. Nelson, J. Laganiere, B. Boyle, J. J. Lum, Y. Doyon

This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.

bioRxiv · Sep 14, 2023 · PreprintCancer Biology

The spatially resolved tumor microenvironment predicts treatment outcome in relapsed/refractory Hodgkin lymphoma

T. Aoki, A. Jiang, A. Xu, Y. Yin, A. Gamboa, K. Milne, K. Takata, T. Miyata-Takata, S. Wu, M. Warren, C. Strong, T. Goodyear, K. Morris, L. C. Chong, M. Hav, , C. Steidl

The paper develops a prognostic model using spatially resolved tumor microenvironment features to predict treatment outcomes in relapsed/refractory Hodgkin lymphoma.

bioRxiv · May 19, 2023Cancer Biology

1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer

M. K. Kilgour, S. MacPherson, L. Zacharias, S. Keyes, B. Pauly, B. Allard, J. Smazynski, P. H. Watson, J. Stagg, B. H. Nelson, R. J. DeBerardinis, P. T. Hamilton, J. J. Lum

This study identifies 1-methylnicotinamide (MNA) as an immune regulatory metabolite in high-grade serous ovarian cancer, showing its role in modulating T cell function through non-cell autonomous mechanisms.

bioRxiv · May 5, 2020Immunology

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

A. Miranda, P. T. Hamilton, A. W. Zhang, E. Becht, A. Mezheyeuski, J. Bruun, P. Micke, A. De Reynies, B. H. Nelson

The paper assesses the relationship between cancer stemness and immune response across 21 solid cancers, finding negative associations between stemness and anticancer immunity.

bioRxiv · Jun 20, 2018Cancer Biology